Last updated 2026-06-18
- Raised $5.7M funding round, Feb 2013
- Raised $9M funding round, Jul 2010
- Raised $4M funding round, Feb 2016
Total raised
$26.2M
Last: 2016-02
Stage
Series A
Founded
2010
Headcount
1-10
HQ
Yavne, Israel
Sector
Health Tech & Life Sciences
About
Avraham Pharmaceuticals is an emerging pharmaceutical company developing novel products for the treatment and prevention of neurodegenerative disorders such as Alzheimer's disease, Lewy body disease, and Parkinson's disease. The company's lead product candidate, Ladostigil, was exclusively in-licensed from the Hebrew University and the Technion and is in phase 2 clinical studies for mild cognitive impairment (MCI). Ladostigil is a multifunctional compound that combines neuro-protective mechanisms, reducing oxidative stress and microglial activation while inhibiting pro-inflammatory cytokines. Ladostigil may have the potential to slow the progression of Alzheimer's disease in patients diagnosed with MCI.
Funding history · 5 rounds · $26.2M total
2016-02
2014-09
2013-02
Q&A
- What is the current status of Avraham Pharmaceuticals?
- Avraham Pharmaceuticals is currently inactive and ceased to operate in July 2018.
- What is Avraham Pharmaceuticals' primary focus?
- Avraham Pharmaceuticals focuses on the prevention of neurodegenerative disorders, developing novel products for conditions such as Alzheimer's disease, Lewy body disease, and Parkinson's disease.
- What is the lead product candidate for Avraham Pharmaceuticals?
- Avraham Pharmaceuticals' lead product candidate is Ladostigil, which was in-licensed from the Hebrew University and the Technion. It is in phase 2 clinical studies for mild cognitive impairment (MCI).
- What is the total amount of funding raised by Avraham Pharmaceuticals?
- Avraham Pharmaceuticals has raised a total of $26,200,000 across multiple funding rounds.
- When was Avraham Pharmaceuticals founded?
- Avraham Pharmaceuticals was founded in February 2010.
- Which investors participated in Avraham Pharmaceuticals' February 2016 funding round?
- In February 2016, Avraham Pharmaceuticals received funding from Clal Biotechnology Industries (CBI) and Integra Holdings.
- What is the employee count for Avraham Pharmaceuticals?
- Avraham Pharmaceuticals has 1-10 employees.
- What is the primary sector of Avraham Pharmaceuticals?
- Avraham Pharmaceuticals operates in the Health Tech & Life Sciences sector.
Team · 3
Founder · Scientific Founder
Founder · Scientific Founder
Founder · Scientific Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
alzheimers-diseasedegenerative-diseasesneurologypharmaceuticalspharma-companiesseniorsparkinson
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/5960707 |
Identifiers & details
| Founded | 2010-2 |
|---|---|
| Status reason | Non Active, Jul 2018 ceased to operate |